Literature DB >> 1815965

Electrophysiological effects of intravenous rilmenidine in man.

J Tonet1, C Guillet, G Jondeau, F Poulain, P Vivet, R Frank, Y Grosgogeat.   

Abstract

Ten patients (44 y), 6 with the Wolff-Parkinson-White syndrome, and none with hypertensive disease, underwent electrophysiological studies before and after intravenous infusion of a single dose of 1 mg rilmenidine administered over 15 min. The regimen produced a mean plasma rilmenidine concentration of 3.16 ng.ml-1 at the end of the infusion. There was no significant change in sinus cycle length, PR interval, QRS, QT duration or in PA, AH and HV intervals. Estimated sinoatrial conduction time and corrected sinus node recovery time did not significantly change. In one patient, however, an abnormal pause was noted after termination of rapid atrial pacing. The right atrial effective refractory period decreased from 209 to 194 ms. There was no significant change in the anterograde and retrograde block cycle length or in the refractoriness of the nodal, ventricular and accessory pathways. The cycle length of induced reciprocating tachycardia decreased slightly from 374 to 351 ms. No patient exhibited an abnormal response to the carotid sinus massage. The findings indicate that intravenous administration of 1 mg rilmenidine exerts modest effects on the electrophysiological parameters of the human heart.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1815965     DOI: 10.1007/BF00314981

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  29 in total

1.  Participation of cardiac presynaptic alpha 2-adrenoceptors in the bradycardiac effects of clonidine and analogues.

Authors:  A de Jonge; P B Timmermans; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-08       Impact factor: 3.000

2.  Quantitative analysis of S3341 in human plasma and urine by combined gas chromatography-negative ion chemical ionization mass spectrometry: 15 month inter-day precision and accuracy validation.

Authors:  H L Ung; J Girault; M A Lefebvre; A Mignot; J B Fourtillan
Journal:  Biomed Environ Mass Spectrom       Date:  1987-06

3.  Adverse effects of sympatholytic agents in patients with hypertension and sinus node dysfunction.

Authors:  M M Scheinman; H C Strauss; G T Evans; C Ryan; B Massie; A Wallace
Journal:  Am J Med       Date:  1978-06       Impact factor: 4.965

4.  Cardiac toxicity of clonidine.

Authors:  P L Williams; J M Krafcik; B B Potter; J H Hooper; M J Hearne
Journal:  Chest       Date:  1977-12       Impact factor: 9.410

5.  Rilmenidine selectivity for imidazoline receptors in human brain.

Authors:  G Bricca; M Dontenwill; A Molines; J Feldman; E Tibirica; A Belcourt; P Bousquet
Journal:  Eur J Pharmacol       Date:  1989-04-25       Impact factor: 4.432

6.  Interaction of clonidine and rilmenidine with imidazoline-preferring receptors.

Authors:  V Lachaud; I Coupry; R A Podevin; J P Dausse; E Koenig; A Parini
Journal:  J Hypertens Suppl       Date:  1988-12

7.  [Evaluation of the response to the ajmaline test in the diagnosis of paroxysmal atrioventricular blocks].

Authors:  J L Tonet; R Frank; G Fontaine; M R Lajeuncomme; J Vedel; J C Petitot; R Coutte; Y Grosgogeat
Journal:  Arch Mal Coeur Vaiss       Date:  1983-10

8.  Isolation and partial purification of a clonidine-displacing endogenous brain substance.

Authors:  D Atlas; Y Burstein
Journal:  Eur J Biochem       Date:  1984-10-15

9.  Noninvasive study of cardiac structure and function after rilmenidine for essential hypertension.

Authors:  A N'guyen van Cao; B Levy; R Slama
Journal:  Am J Cardiol       Date:  1988-02-24       Impact factor: 2.778

10.  Cardiovascular and central nervous system effects of rilmenidine (S 3341) in rats.

Authors:  E Koenig-Berard; C Tierney; B Beau; G Delbarre; F Lhoste; C Labrid
Journal:  Am J Cardiol       Date:  1988-02-24       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.